Your browser doesn't support javascript.
A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses.
Chen, Sisi; Yang, Liu; Ou, Xia; Li, Jin-Yu; Zi, Cheng-Ting; Wang, Hao; Hu, Jiang-Miao; Liu, Ye.
  • Chen S; Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650000, Yunnan, China.
  • Yang L; State Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China.
  • Ou X; School of Medicine, Kunming University of Science and Technology, Kunming, 650201, Yunnan, China.
  • Li JY; State Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China.
  • Zi CT; College of Science, Yunnan Agricultural University, Kunming, 650201, Yunnan, China.
  • Wang H; CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, CAS Center for Excellence in Nanoscience, Beijing, 100190, China. wanghao@nanoctr.cn.
  • Hu JM; State Key Laboratory of Phytochemistry and Plant Resources in West China, and Yunnan Key Laboratory of Natural Medicinal Chemistry, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China. hujiangmiao@mail.kib.ac.cn.
  • Liu Y; Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, 650000, Yunnan, China. liuye@imbcams.com.cn.
J Nanobiotechnology ; 20(1): 320, 2022 Jul 14.
Article in English | MEDLINE | ID: covidwho-2254631
ABSTRACT

BACKGROUND:

Nanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that end, it is critical for obtaining a potent self-adjuvant platform to assemble with different types of antigens into nanovaccines.

RESULTS:

In this study, we identified a new natural polysaccharide from the rhizomes of Bletilla striata (PRBS), and used this polysaccharide as a platform to construct diverse types of nanovaccines with potent self-adjuvant property. In the construction process of SARS-CoV-2 nanovaccine, PRBS molecules and RBD protein antigens were assembled into ~ 300 nm nanoparticles by hydrogen bond. For HIV nanovaccine, hydrophobic effect dominantly drove the co-assembly between PRBS molecules and Env expression plasmid into ~ 350 nm nanospheres. Importantly, PRBS can potently activate the behaviors and functions of multiple immune cells such as macrophages, B cells and dendritic cells. Depending on PRBS-mediated immune activation, these self-adjuvant nanovaccines can elicit significantly stronger antigen-specific antibody and cellular responses in vivo, in comparison with their corresponding traditional vaccine forms. Moreover, we also revealed the construction models of PRBS-based nanovaccines by analyzing multiple assembly parameters such as bond energy, bond length and interaction sites.

CONCLUSIONS:

PRBS, a newly-identified natural polysaccharide which can co-assemble with different types of antigens and activate multiple critical immune cells, has presented a great potential as a versatile platform to develop potent self-adjuvant nanovaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: J Nanobiotechnology Year: 2022 Document Type: Article Affiliation country: S12951-022-01533-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: J Nanobiotechnology Year: 2022 Document Type: Article Affiliation country: S12951-022-01533-3